NASDAQ:IMMU Immunomedics (IMMU) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free IMMU Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$87.86▼$87.8650-Day Range$85.08▼$87.8652-Week Range$8.80▼$87.93VolumeN/AAverage Volume4.01 million shsMarket Capitalization$20.31 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immunomedics alerts: Email Address Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Immunomedics Stock (NASDAQ:IMMU)Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.Read More Ad Weiss RatingsThe ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. IMMU Stock News HeadlinesMarch 6, 2024 | finance.yahoo.comGilead bets on ‘trispecifics’ in latest cancer drug dealFebruary 29, 2024 | finance.yahoo.comAbingworth invests in Trodelvy development in deal with GileadMarch 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.February 13, 2024 | msn.comGilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to PipelineFebruary 12, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead: Maintaining Our $97 Fair Value Estimate as CymaBay Acquisition Looks Like a Good FitFebruary 12, 2024 | finance.yahoo.comGilead to buy CymaBay in $4.3B deal for liver disease drugFebruary 7, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead Earnings: Maintaining $97 Fair Value Estimate as HIV and Oncology Catalysts ApproachJanuary 22, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead: Trodelvy Lung Cancer Data Disappoints, but No Changes to Our Fair Value EstimateMarch 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 16, 2024 | finance.yahoo.comArvinas Appoints Jared Freedberg as General CounselJanuary 9, 2024 | finance.yahoo.comNeuroTrauma Sciences Appoints William Fricker, CPA, MBA, as Chief Financial OfficerNovember 15, 2023 | benzinga.comGilead Sciences's Options: A Look at What the Big Money is ThinkingNovember 9, 2023 | benzinga.comA Closer Look at Gilead Sciences's Options Market DynamicsNovember 8, 2023 | finance.yahoo.comGilead Sciences, Inc.: Gilead Earnings: Maintaining Our $97 FVE Following In-Line HIV and Oncology PerformanceNovember 6, 2023 | bizjournals.comGilead sues former CFO of Immunomedics to claw back $4 millionNovember 6, 2023 | bizjournals.comDaily Digest: Slack CEO departs; Big East Bay battery factory opensOctober 29, 2023 | realmoney.thestreet.comSpate of Deal News Juices Start of This Week's TradingSeptember 14, 2023 | finance.yahoo.comUnraveling Gilead Sciences Inc's Dividend Performance and SustainabilityAugust 24, 2023 | uk.finance.yahoo.comAntibody Drug Conjugate (ADC) Markets, 2035August 13, 2023 | morningstar.com8 Undervalued Quality Healthcare StocksAugust 4, 2023 | finance.yahoo.comGilead Sciences, Inc.: Gilead's HIV Dominance and Growing Oncology Portfolio Support a Wide MoatJuly 19, 2023 | thestreet.comImmunomedics, Seattle Genetics Lead Biotech Movers on Deal NewsJuly 11, 2023 | finance.yahoo.comLooking For Attractive Uncorrelated Returns in a Highly Uncertain Market? Consider Merger ArbitrageJune 22, 2023 | marketwatch.comThe global Cell therapy Processing market Size during the period of 2023 to 2030 is expected grow at CAGR of 9.1%May 18, 2023 | msn.comEuropean shares slip on US debt ceiling concernsMay 17, 2023 | reuters.comASIA Japan leads the way, China feels the heatMay 17, 2023 | msn.comFormer Immunomedics CFO pleads guilty to insider tradingSee More Headlines Receive IMMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2020Today3/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryBiotechnology Current SymbolNASDAQ:IMMU CUSIP45290710 CIK722830 Webwww.immunomedics.com Phone973-605-8200FaxN/AEmployees366Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-357,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.40% Return on Assets-51.32% Debt Debt-to-Equity RatioN/A Current Ratio12.84 Quick Ratio12.58 Sales & Book Value Annual Sales$290,000.00 Price / Sales70,028.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book63.67Miscellaneous Outstanding Shares231,144,000Free FloatN/AMarket Cap$20.31 billion OptionableOptionable Beta2.90 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Behzad Aghazadeh Ph.D. (Age 49)Exec. Chairman Comp: $147.53kMr. Usama Malik (Age 45)CFO & Chief Bus. Officer Comp: $533.39kMr. Brendan P. Delaney (Age 45)Chief Commercial Officer Comp: $527.63kMr. Bryan Ball (Age 50)Chief Quality Officer Comp: $646.48kMr. William Fricker (Age 55)Principal Accounting Officer, Exec. Director & Corp. Controller Ms. Phyllis ParkerDirector of Admin.Dr. Chau ChengSr. Director of Investor RelationsMr. Jared Freedberg (Age 52)Gen. Counsel & Corp. Sec. Mr. Kurt J. W. Andrews (Age 51)Chief HR Officer Dr. Loretta M. Itri (Age 70)Chief Medical Officer More ExecutivesKey CompetitorsCooper CompaniesNASDAQ:COOGenmab A/SNASDAQ:GMABKoninklijke PhilipsNYSE:PHGWatersNYSE:WATIlluminaNASDAQ:ILMNView All Competitors Should I Buy Immunomedics Stock? IMMU Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Immunomedics was last updated on Friday, March 15, 2024 at 3:50 AM. Pros Here are some ways that investors could benefit from investing in Immunomedics, Inc.: Immunomedics, Inc. has a strong pipeline of monoclonal antibody-based products, including sacituzumab govitecan for metastatic triple-negative breast cancer. The company has collaborations with major pharmaceutical companies like AstraZeneca and F. Hoffman-La Roche Ltd, indicating industry recognition and potential for growth. Recent partnership announcements, such as the one with Gilead Sciences, show the company's ability to expand into new biologic drug territories, enhancing its market presence. Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc., providing financial stability and potential synergies for further development. Investors may find the current stock price of Immunomedics, Inc. attractive for potential gains based on market trends and growth prospects. Cons Investors should be bearish about investing in Immunomedics, Inc. for these reasons: The biotechnology industry, where Immunomedics operates, can be highly competitive and subject to regulatory challenges, impacting the company's growth potential. Market volatility and uncertainties in the healthcare sector could affect the stock performance of Immunomedics, Inc., leading to potential investment risks. Dependency on a few key products, such as sacituzumab govitecan, for revenue generation may pose a risk if these products face setbacks in clinical trials or regulatory approvals. Changes in healthcare policies or regulations could impact the pricing and reimbursement of Immunomedics' products, affecting the company's financial performance. Investors should carefully consider the overall market conditions and the competitive landscape before making investment decisions related to Immunomedics, Inc. IMMU Stock Analysis - Frequently Asked Questions How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.39. The biopharmaceutical company had revenue of $20.07 million for the quarter, compared to analyst estimates of $24.81 million. What other stocks do shareholders of Immunomedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Micron Technology (MU), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Intel (INTC). This page (NASDAQ:IMMU) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBitcoin dollar warningStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.